NicOx S.A. and Merck have expanded their worldwide license agreement following the discovery of a new approach to nitric oxide (NO) donation in their joint research program. This approach may be used to develop new classes of NO-donating new molecular entities (NMEs) designed to offer a different mechanism for controlling the delivery of NO, while retaining the potential therapeutic benefits. NO is an endogenous cell-signaling molecule and there is evidence, according to the companies, that ...